Revolutionizing Nucleic Acid Synthesis with Engineered Enzymes

David Entwistle, Ph.D., Head of Process Chemistry, Codexis

Revolutionizing Nucleic Acid Synthesis with Engineered Enzymes

Click to watch video

Nucleic acid is a burgeoning field of endeavor in the pharmaceutical sector. From high profile mRNA vaccines to the next wave of complex oligonucleotides, biocatalytic processes are starting to deliver on their promise to not only improve product quality but also, synthetic efficiency, sustainability and scalability. We will present our progress on a range of highly engineered enzymes and their integration into efficient workflows and processes for the scalable manufacturing of therapeutic nucleic acids.

David Entwistle is the Head of Process Chemistry at Codexis, leading the company’s research efforts in sustainable chemistry programs for both small molecule therapeutics manufacturing and enzymatic oligonucleotide synthesis. Prior to joining Codexis in 2012, he was a synthetic organic chemist for Pfizer Process Chemistry in the UK for over a decade, working on many early- to mid-clinical phase APIs. David obtained his Ph.D. from Imperial College London in 1994 under Prof. Steve Ley FRS. His postdoctoral positions with Prof. Tomas Hudlicky and Prof. Gerry Pattenden FRS focused on synthetic organic methodologies and total synthesis.